No Data
No Data
KeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
AbCellera Biologics Is Maintained at Overweight by Keybanc
AbCellera Biologics Is Maintained at Overweight by Keybanc
AbCellera Biologics Price Target Cut to $7.00/Share From $8.00 by Keybanc
AbCellera Biologics Price Target Cut to $7.00/Share From $8.00 by Keybanc
Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7
Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target from $8 to $7.